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SCREENING OF CRUDE MICROALGAL EXTRACTS FOR ANTIMICROBIAL ACTIVITY
Patrick T. Matulich
University of the Incarnate Word, 2019
Microbial biofilm associated infections are a significant threat to patients with medical
devices and are partially responsible for the increased resistance seen in nosocomial infections.
The biofilm chemical and physical properties restrict access of chemotherapeutic agents.
Therefore, there is a need to enhance the antimicrobial effects of current chemotherapeutic
agents. Microalgae live in competitive environments that include film-forming, opportunistic
pathogens S. maltophilia and C. albicans. Extracts from 5 diverse species of microalgae were
screened for antimicrobial enhancing effects against established biofilms with two different
extraction solvents, 3:1 hexanes and isopropyl (HIPA) and 2-methyltetrahydrofuran (2-MTHF).
Three species, B. braunii, C. danica, and N. oculata showed statistically significant
reduction in cell viability of S. maltophilia in an established biofilm (p < 0.001, p < 0.001, and p
< 0.001, respectively). An extract of 2-MTHF, N. oculata [M], showed enhancing effects of
ceftriaxone against S. maltophilia in an established biofilm. Furthermore, B. braunii, C. danica,
and N. oculata extracts showed a statistically significant reduction in cell viability of C. albicans
in combination with fluconazole (p = 0.003, p = 0.002, and p = 0.021, respectively). Based on
our findings, additional research should focus on the organic components of N. oculata, B.
braunii, C. danica that contribute to reduced microbial cell viability in established biofilms.
Furthermore, data suggests that 2-MTHF is a viable solvent for future extraction processes.
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Background
Bacteria
Bacteria are an expansive group of microscopic prokaryotic organisms. They are found
everywhere, including environments previously thought to uninhabitable.1–3 Despite their
immense genetic diversity, bacteria share common structural features (see Figure 1.0). One of the
most studied and medically important structures is the bacterial cell wall. All bacteria species
have a cell wall made of a peptidoglycan, a sugar and protein polymer. The cell wall is rigid to
provide structural support, and has components that are vital to cell-to-cell communication.4
Cell wall
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Figure 1. General bacterial cell and significant structures. Original image created with Adobe
Illustrator.
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Gram Negative. The broadest way to categorize bacterial species is based on their cell
wall structure. The thickness of this cell wall helps categorize bacteria as gram-positive or gramnegative. A gram-positive bacterium has a thick peptidoglycan cell wall that easily retains crystal
violet (see Figure 2a). Conversely, a gram-negative bacterium has a significantly thinner cell
wall. In addition, gram-negative organisms have a lipopolysaccharide (LPS) outer membrane
which covers the cell wall (see Figure 2b). The differences in cell wall structure are crucial in
drug development, as5–7 antibiotics target the cell wall￼must be transported through the cell
wall.5–7

Figure 2. Gram-positive
cell wall structure derived
from Irving’s Medical
Microbiology.4 Original
image created with Adobe
Illustrator.

Figure 3. Gram-negative
cell wall structure derived
from Irving’s Medical
Microbiology.4 Original
image created with Adobe
Illustrator.
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Bacterial Resistance. As early as the 1940s, when penicillin was introduced to the
market, there was already limited evidence of a reduced sensitivity to the beta-lactam over
time.8,9 These first signs of insensitivity to antibiotics foreshadowed the imminent rise of the
modern resistance era. Yet, the long-term effects of resistance were largely dominated by our
ability to find new antibiotics. However, in the 1960’s drug discovery slowed greatly while
resistance continued to accumulate (see Figure 3).10,11 Now, the world is facing a surge in
antimicrobial resistance which is, again, shifting our paradigm of treatment options.

Figure 4. Timeline of drug discovery vs. the emergence of resistance to select antibiotics.
Timeline was created with Adobe Illustrator. Data for the timeline was obtained through the
CDC’s 2013 report “Antibiotic Resistance Threats in the United States” 12
Physical Resistance. Many antibiotics target the rigid, peptidoglycan cell wall of
bacteria.13 Through cell wall disruption, the bacteria’s structure becomes unstable and vulnerable
to lysis from external pressures. However, gram-negative bacteria have an outer-membrane that
restricts access to the cell wall through pores. The LPS is a significant physical barrier for novel
antibiotics, and has limited the number of effective compounds against gram-negative
bacteria.5,6,14 The physical membrane surrounding the cell provides a rudimentary level of
resistance while bacterial genes provide more sophisticated mechanisms to evade antibiotic
destruction.
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Genetic Resistance. In recent decades, genetic resistance has exploded into a global
crisis due to the exponential increase in incidence and accumulation of resistance genes within
microbes.12 Resistance genes can be integrated into the single chromosome of a bacteria or, more
often, are located on an extrachromosomal plasmid (R plasmid).15,16 As reviewed by Van Hoek,
resistance genes have varying degrees of effectiveness, specificity, and often number in the
hundreds.17 R plasmids can accumulate resistance genes; in turn, making an organism multidrug
resistant (MDR). Through the selective pressures of antibiotics, R plasmids are now seen at
much higher rates in nature.15
Horizontal gene transfer. Horizontal gene transfer (HGT) is a ubiquitous mechanism of
almost all bacteria and involves the exchange of genetic material across species or strains.18–20
HGT is vital to the evolutionary progression of bacteria. Nearly all resistance genes in bacteria
are found on transposable elements or linked to transposable elements within the genome. The
transposable nature of resistance genes means that they are capable of being easily integrated
into a genome (see Figure 4).15,16,18,20–22 Thus, through HGT a resistant pathogen can transfer the
associated resistance genes to another species. HGT is not limited to resistance genes. It is also
attributed in conferring virulence factors that make non-pathogenic bacteria pathogenic.15,16,20
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Figure 5. Accumulation of genetic resistance via conjugation. 1) When bacterial cells come
within proximity, they can exchange genetic information through a pili. This method of genetic
exchange is called, conjugation. Bacterial cells can transfer copies of their plasmid to a cell that
lacks a plasmid. 2) Resistance genes are located on transposable elements which can easily be
translocated back and forth between the chromosome and plasmid. A plasmid can accommodate
multiple genes to confer multi-drug resistance. 3)A plasmid with resistance genes can be
transferred to a non-plasmid cell, again, through conjugation. 4) Resistance genes have now been
transferred to a previously non-resistant cell.15 Original image created with Adobe Illustrator.
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Fungi
Fungi represent a completely different biological set of microbes and are classified under
the Eukarya domain accordingly. Their life cycle, molecular structures, and metabolisms are
radically different than bacteria. Unlike bacteria, fungi have defined membrane bound
organelles, which are also found in animal cells (see Figure 5).4 Due to the cellular similarities
between fungi and humans, treatment options for serious fungal infections are limited and carry a
high risk of toxicity.23–25
Often, fungal infections are associated with superficial skin infections, but they can cause
much more serious illnesses through invasive fungal infections (IFI). Diagnosis of fungal
infections is often delayed because they are relatively less common in contrast to viral and
bacterial infections but trigger similar initial symptoms. All these factors lead to dangerous
mortality rates among mycotic associated infections, as high as 95% in some instances.26,27

Cell Wall
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Figure 6. General structure and components of a fungal cell derived from Irving’s Medical
Microbiology.4 Original image created with Adobe Illustrator.
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Most fungal species live commensally in the environment and on other organisms. When
disturbances occur in the normal flora of an organism or its immune system becomes
compromised, these commensal fungi can cause dysfunction or disease. In most instances,
invasive fungal infections are seen in immunocompromised or immunosuppressed patient
populations: HIV/AIDS patients, cancer patients, and transplant recipients.26–28 Misdiagnosis of
invasive fungal-related deaths has made it difficult to accurately estimate its impact, but, as
reviewed by Brown, IFIs account for more deaths than malaria or tuberculosis annually.
Fungal Resistance. The number of effective antifungal agents is significantly less than
antibiotics, with a total of five different classes used for IFIs: azoles, echinocandins, polyenes
and pyrimidines.24 Nevertheless, antifungal agent discovery and resistance share motifs with
antibiotics and bacterial resistance. Many antifungal drugs were discovered in the 60s, but many
IFIs are now showing decreased sensitivity to them.25,28,29 Fungal resistance is of great concern
because of the limited number of safe, effective drugs available.
As opposed to bacterial binary fission, fungi undergo sexual reproduction. Thus, the
resistance genes do not spread through HGT, but through recombination of genes. The genes can
then be carried through populations without dominant expression. There are several genetic
based mechanisms that help fungi avoid destruction by chemotherapeutic agents, mainly drug
efflux pumps.28,30,31 However, another mechanism of clinical significance is its robust ability to
form biofilms, which are discussed shortly.
Biofilms
Bacteria and fungi are capable of adhering tightly to biotic and abiotic surfaces through
the formation of biofilms.32–35 Biofilms are complex infrastructure made of extracellular
proteins, polysaccharides, and genetic material. The biofilm creates a protective haven for the
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founding organisms and other microbes, bacterial or fungal. Through the formation of a biofilm,
a diverse community of organisms can exchange genetic information, store nutrients, and protect
themselves from physical removal and chemotherapeutic agents (Figure 6).28,30,33,35–37
Formation. A major challenge to combating resistant microbes are their ability to form
biofilms. Bacterial biofilm formation is moderated by cellular appendages like flagella and pilli
(see Figure 1). Biofilms are established in the presence of a viable surface and hospitable

Figure 7. The process of biofilm formation and its contributions to antibiotic resistance. 1)In
favorable conditions, bacteria can begin the process of adhesion to a surface, 2) once attached,
the bacteria begins excreting the components to form a biofilm, 3) the newly formed surface
promotes adhesion of other transient bacteria, 4a) the microbial community shares genes through
horizontal gene transfer, 4b)the mature biofilm confers resistance to antibiotics (ABX),
disinfectants (AH+ and B-), and other environmental stressors.33 Original image created with
Adobe Illustrator.
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living conditions, such as a water source. Thus, medical devices are a primary source of biofilm
related infections.31,38–40
Once a surface is detected, the organism begins to undergo genetic changes that promote
film-specific cellular processes. The organism adheres to the surface through excretion of surface
binding proteins.30,35 In addition to the binding proteins, the organism may secrete a range of
long polysaccharide chains, extracellular proteins, genetic material, and fatty acids creating an
extracellular matrix (ECM).30,33,41 The ECM encases the cells—creating a protective barrier from
the environment and a favorable surface for additional cellular adherence. As more cells attach
and new generations form, they contribute to the construct of the biofilm. The film can store
nutrients, send cellular signals, and protect the microbes physical and chemically. Additionally,
the biofilm shields microbes from therapeutic drug concentrations and the host immune
cells.33,35,37,41
Persister Cells. Upon establishment of an ECM, some cells will undergo drastic changes
in their genetic expressions.30,33,35,42 They lower their metabolic activity and begin to upregulate
proteins specific to biofilm maintenance. These metabolically inactive cells are called persister
cells, and exist as a fundamental element in many fungal and bacterial biofilms.43,44 The ECM
protects persister cells from exposure, and their slowed metabolism greatly reduces the efficacy
of chemotherapeutic agents. Their presence helps to continue cell proliferation within the
biofilm.
Economic Implications of Resistant Infections
The economic burden of resistant infections is difficult to measure, and there continues to
be debate on how to properly calculate its effects. However, according to a report released by the
CDC, the direct cost of resistant infections is estimated at $20 billion with an additional $25
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billion of indirect cost.12,29 In response to the inflating cost associated with resistance, the US has
increased regulations on antimicrobial prescriptions. Regulatory solutions like this may help curb
the rapid growth of resistance across microbes, but ultimately has dampened interest in
antimicrobial research.45–47 If novel compounds are discovered, they likely will be used as a last
resort—limiting their profitability.
Health Disparities. Many first-line antimicrobials can be produced on a commercial
scale at relatively low cost; providing an efficient means of delivering healthcare to low-income
and middle-income citizens, especially to those in developing nations. Due in part to their
widespread, unregulated use, antibiotic resistance is becoming more common among such
populations.12,18 Since treatment for resistant organisms is often more expensive, the progression
of resistance is creating a more rigid health disparity worldwide.
Antimicrobial Agents
Antibiotics. As far back as 300 CE, there is evidence that humans had discovered
mysterious, natural healing powers among soil dwelling fungi.22 However, our understanding of
the microbial world and the ability to isolate such compounds limited their potential until the
early 20th century. With the commercialized success of penicillin in 1942, the “Golden Age” of
antibiotics had begun.8,14,46
The widespread success of penicillin in preventing infection related deaths was quickly
followed by the discovery of streptomycin in 1943, which became the first treatment effective
against tuberculosis.7,48 While penicillin was synthesized from a fungus, Penicillin notatum,
streptomycin was synthesized from a soil bacterium, actinomycetes. These first discoveries
provided a framework for future antibiotic research and led scientists to scour soil
microenvironments for additional antibiotic producing microbes.14 Through the 1960’s hundreds
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of antibiotics were discovered this way, representing up to twenty different classes. The scope of
this research includes agents from two of these classes, monobactams and cephalosporins which
are structurally related.
β-lactams. β-lactams are a copious class of antibiotics that are all feature derivatives of a
beta-lactam ring. Due to the numerous members in this broad class, they are further divided into
four sub-classes based on chemical substituents around the beta-lactam ring: penicillins,
cephalosporins, carbapenems, and monobactams (see Figure 7a-d).7 They all share a similar
mode of action—inhibiting cell wall synthesis through interactions with penicillin binding
proteins (PBPs).11 PBPs are membrane bound proteins that are essential to the growth of a
bacterium. As the cell divides through binary fission, it must rapidly synthesize the growing cell
wall. The cell wall, made mainly of a complex sugar peptidoglycan, is synthesized in part by
PBPs which help cross-link rigid, foundational units. β-lactams are, structurally, similar to these
foundational units; thus, PBPs have an affinity to bind with them.7,10,49,50 In turn, the enzyme
becomes inactivated, which ultimately prevents further cross-linking within the cell wall.15 The
result is a weakened cell wall that is susceptible to external pressures and cell lysis.

Figure 8. General structure for penicillins. Public
domain image.

Figure 9. General structure for
carbapenems. Public domain image.
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Figure 10. General structure for cephalosporins.
Public domain image.

Figure 11. General structure for
monobactams. Created with ChemDraw
Professional 16

Aztreonam. Monobactams, are a relatively small subclass of beta-lactams. They are easily
identified by the singular four-membered beta-lactam ring. They are of significant clinical
significance for a couple of reasons: 1) their relatively simple structure enables total synthesis,
and 2) they are highly specific to penicillin-binding protein 3 (PBP-3).7,11,13,49 Aztreonam (see
Figure 8) was the first of this subclass to be introduced in 1986. Its fully synthetic nature lowers
instances of allergic reactions found in traditional beta-lactams that are produced by fungi—
penicillins and cephalosporins.7,9,11 It is freely soluble in water, and has a narrow specificity for
mostly aerobic, gram-negative bacteria due to its interaction with PBP-3.51 This feature helps to
reduce disruptions in normal flora of the host, which occurs commonly with other antibiotics.

Figure 12. Chemical structure of aztreonam. Note the beta-lactam ring with substituents, and no
additional fused ring. Public domain image.
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Ceftriaxone. Analogous to the sub-class of penicillins, cephalosporins were discovered as
a natural product of a fungus, Cephalsporium.52 As with other β-lactams, they comprise of a
beta-lactam ring with extensive modifications to the side-chains that interfere with cell wall
synthesis. Cephalosporins have progressed since their first discovery in the 1940s through
synthetic modifications, and are now classified as generations: first, second, third, and fourth.52,53
Ceftriaxone (see Figure 9), a water-soluble, third-generation cephalosporin, is known for its
effectiveness against gram-negative bacteria through interaction with PBPs.53–55 Its introduction
in the 1980’s helped treat bacterial infections that had become insensitive to penicillins.

Figure 13. Chemical structure for ceftriaxone. Note the central beta-lactam ring with an
additional fused ring and side chains. Public domain image.
Antifungals. As mentioned, antifungals present a greater challenge in therapeutic use
because of the cellular similarities between fungal cells and animal cells. Thus, many effective
antifungals pose a serious risk of toxicity to patients. Rising resistance to first-line treatment and
limited classes of safe antifungal agents has begun to strain the capacity for positive outcomes
from IFIs.28,31,56–58
Fluconazole (see Figure 10) is part of the azole class of antifungal agents that target the
ergosterol biosynthesis pathway by inhibiting a cytochrome P450 (CYP51) enzyme lanosterol
14-α-demethylase (EC 1.14.13.70).25,58 Ergosterol is an essential membrane component unique
to fungi. However, CYPs exhibit widespread expression among eukaryotes, and are particularly
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important in human liver cells where they participate in xenobiotic metabolism and
detoxification. Thus, interactions of azole antifungals with P450 enzymes present drug
interaction risks stemming from their interference with the metabolism of other drugs.59,60 It
remains a common first line treatment because of its low cost and broad specificity.
Fluconazole’s widespread use has led to increasing resistance among common fungal genera,
especially Candida— with 7% of Candida clinical isolates currently demonstrating resistance to
fluconazole.61

Figure 14. Fluconazole chemical structure. Public domain image.
Microalgae
Microalgae represent an incredibly diverse group of photoautotrophic and heterotrophic
unicellular organisms that live in marine, freshwater, or damp soil environments.62,63 Compared
to other microbial species, microalgae grow slowly and are labor intensive to maintain. However,
interest in natural products has returned in recent years as a means of offsetting biofuels
production costs with secondary products and applications. Microalgae species are now used in
an array of applications including: biofuel production, wastewater treatment, livestock feed,
cosmetics, nutraceuticals, and antimicrobial compounds.23,64–69
Algal Extracts. Macroalgae and microalgae species have been shown to possess quorumquenching metabolites, and to interact with bacterial populations.70,71 Quorum-quenching
molecules are capable of disrupting microbial cell-signaling. Moreover, studies have identified
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that algal-associated bacteria are often capable of producing quorum-quenching and bactericidal
compounds.72 Extracts of algal cells are rich in known compounds (antioxidants, flavonoids, and
polyphenols) that exhibit diverse effects such as: anti-inflammatory, anti-cancer, or antimicrobial
activity.67,68,73–78 Methods for extracting such active components are as diverse as the algae
themselves.
Antioxidants. Antioxidants represent a broad class of molecules capable of neutralizing
reactive oxygen species (ROS) and are found naturally in many plants and algae. Through
routine cellular processes, ROS can readily form and cause damage to cellular components. For
this reason, a great deal of research in has focused on using antioxidants to prevent cellular
damage and reduce cancer risks.73,79 Yet, antioxidants have also been recognized for their
antimicrobial activity in plants. For example, phytoalexins are a group of polyphenolic
compounds that accumulate in localized fungal, viral, or bacterial infections in plants.80–82
Polyphenols. Polyphenols are a well-studied, diverse group of secondary metabolites
produced in plants. They are produced as biproducts of metabolic cellular processes, but are
considered essential for the plant’s survival— in particular, as part of their arsenal of defense
mechanisms against fungi, bacteria, viruses, and herbaceous predators.83–86 Polyphenols are
released in response to stressors, infection or predation as a means of preventing further
damage.87,88
According to Stéphane Quideau, a polyphenol must be derived from a phenylpropanoid
and/or the polyketide pathway, feature more than one phenolic unit, and be deprived of a
nitrogen-based functionality.84 With these guidelines, polyphenols are further divided into
subgroups based on chemical structure: flavonoids, nonflavonoids, tannins, and lignins.89,90 In
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general, these compounds are soluble in polar solvents but exhibit limited water solubility.
Therefore, they are typically extracted using methanol or ethanol (see Figure 11a-c).66,85

Figure 15. Quercetin. A flavonol
found in many vegetables. Public
domain image.

Figure 16. Quercitannin. A tannin
found in oak tree bark. Public
domain image.

Figure 17. Nobiletin. A flavonoid
found in citrus fruit. Public
domain image.

Context of Study
Stenotrophomonas maltophilia
S. maltophilia is an aerobic, gram-negative, film-forming bacterium that ubiquitous in
humid or wet environments and colonizes biotic and abiotic surfaces. It is abundant on many
natural surfaces including human skin but is typically non-pathogenic. However, S. maltophilia
has emerged as an increasingly common opportunistic pathogen, especially among
immunocompromised populations.38,91–93 Since it is a gram-negative bacterium, there are limited
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effective chemotherapeutic agents available to combat S. maltophilia infections. Furthermore,
genomic analysis has indicated potential resistance mechanisms for a number of antibiotic
classes that are well conserved.91 With limited treatment options and mortality rates for chronic
S. maltophilia infections as high as 70 percent, S. maltophilia is evolving in both an attractive
and urgent target for intervention. 91,94,95
Biofilm Properties. S. maltophilia forms robust biofilms on surfaces, biotic and abiotic
which greatly increase its resistance to antibiotic targeting.94,96–98 It’s adherence to surfaces is
dependent on hydrophobic properties. Studies show that the flagellum, pilli, and fimbriae
increase its ability to attach to abiotic, hydrophobic surfaces. Visualization of the 3-D EPS
structure shows complex layering of cells and extracellular components with localized
hydrophobic regions.99,100 Cells within the biofilm have an increased hydrophobicity relative to
those grown planktonically.99 The hydrophobic nature of the cells and biofilms may account for
reduced sensitivity to antibiotics since most drugs must be hydrophilic to be distributed
throughout the body.101
At-Risk Populations. S. maltophilia is an emerging pathogen that continues to be
isolated more frequently in hospital acquired infections due to its affinity for damp environments
and ability to colonize a wide variety of surfaces.12 It’s efficient development of resistance
means that the regular use of prophylactic broad-spectrum antibiotics in these patients helps
creates a non-competitive growth environment for S. maltophilia to colonize and infect.102
Medical devices are a common means of transmission, including endoscopes, suction hoses, and
central venous catheters.38,92,98 Unsurprisingly, most clinical isolates are found among critical
care patients with compromising injuries where these devices are in frequent use, along with
broad spectrum antibiotics, for long periods of time. Recent findings suggest that the
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prophylactic use of broad-spectrum antibiotics may contribute significantly to resistant S.
maltophilia infections.94
Like other opportunistic pathogens, S. maltophilia is a serious concern for patients
without an active immune system—a population that is rapidly growing in modern healthcare
settings.27 High-risk patients include those with organ or tissue transplantation, HIV/AIDS,
cystic fibrosis, and cancer. S. maltophilia in these patients is most commonly isolated from upper
respiratory infections; but is also linked to bacteremia, urinary tract infections, and meningitis.91
Candida Albicans
Candida albicans is a fungus that is ubiquitous in the environment that often lives
commensally on skin and areas of the gastrointestinal tract.103 Normally, C. albicans goes
unnoticed and does not disturb its human hosts. However, it is also the main cause of candidiasis,
which can present in the mouth (thrush), vagina (yeast infection), or systemically (invasive
candidiasis).104 Invasive candidiasis has a particularly high mortality rate of 19-24%.
Furthermore, resistance to the first-line drug, fluconazole, is increasing, due in part to the ability
of C. albicans to form biofilms.61
C. albicans forms robust biofilms on biotic and abiotic surfaces, and is the most common
fungal species isolated from clinical biofilms.104 Through the establishment of a biofilm, the
fungus can evade both the immune system and antifungal agents. As with S. maltophilia, a
primary source for nosocomial invasive candidiasis are medical devices such as central venous
catheters, urinary catheters, heart valves, and endotracheal tubes.103
It has been well documented that C. albicans naturally has a hydrophobic cellular surface
through the expression of the cellular surface hydrophobicity (CHS1) gene.105–107 C. albicans
hydrophobicity is enhanced through the process of biofilm formation, and is linked to increased
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virulence.101 Current research demonstrates that hydrophobic compounds have had impacts on
biofilm formation in C. albicans species.108
S. maltophilia and C. albicans are two very different opportunistic pathogens. Yet, they
are both capable of forming biofilms with hydrophobic properties as a prelude to developing
drug resistant, both can reside competitively in similar natural environments, and both organisms
afflict the same human populations.
Microalgal Extracts
Many studies have begun investigating natural sources to enhance antimicrobial activity
of current treatments to pathogens.109–113 Microalgae have already repeatedly shown antibacterial
activity.67,114–117 Algal extracts offer an ideal alternative to increasing traditional interventions
because many species have been labeled as generally accepted as safe (GRAS) and are fully
biodegradable.63 Furthermore, they offer an efficient, environmentally friendly method of
producing potentially complex molecules.118,119 However, there remains large classes of species
which have evaded investigation. The current study uses several species that represent diverse
classes of microalgae (see Figure 13 and Table 1). Our goal is to evaluate known algae species to
determine novel applications and stimulate additional research interest for their antimicrobial
use. We evaluate their efficacy on planktonic growth and established biofilms as compared to
current antibiotics. Additionally, we determine if algae extracts offer enhancing effects when
combined with antibiotics or antifungals, against S. maltophilia and C. albicans, respectively.
It’s theorized that components of the algal extracts can increase the effectiveness of the select
antimicrobials by negating resistance features of bacterial biofilms and their hydrophobic effects.
Recent studies have shown that extracts from lipid producing species such as B. braunii, C.
danica, and N. oculata have measurable antimicrobial effects.115,117,120 However, most of these
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studies have not evaluated the impact on organisms in biofilms, and have not included the gramnegative bacterium S. maltophilia or fungus C. albicans.
Table 1. Algae Species of Interest to the Present Study.
Algae Species

Aquatic Environment

Current Interest or Use

Botryococcus braunii

Freshwater

Biodiesel121,122

Tisochrysis lutea

Marine

Aquaculture feedstock123

Rhodomonas lens

Marine

Aquaculture feedstock124,125

Chlorochromonas danica

Freshwater

Treatment of waste products126,127

Nannochlropsis oculata

Freshwater

Biodiesel128,129

Figure 18. Taxonomical reference of algal species used in current study. Figure is a visual
representation of taxonomy for species and does not depict actual genetic distance or variation
between species shown. All data was collected from algaebase.org, April 1, 2017. Original image
created with Adobe Illustrator.
Extraction Solvents
As with many natural extract experiments, the choice of solvent plays a crucial role in
proper evaluation. A majority of active components are found in organic layers of extraction.
However, it is known that the naturally produced polyphenols and flavonoids have antimicrobial
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activity, and are extracted best with slightly polar solvents.84,130 Therefore, most extraction
methods use a mixed solvent system, using a small amount of polar solvent with a large amount
a non-polar counterpart. One common application is a 3:1 or 3:2 ratio of hexanes-isopropyl or
chloroform–methanol.131 To simplify this process, 2-methyltetrahydrofuran (2-MTHF) is
proposed as a singular solvent in comparison with a mixed solvent method employing hexanesisopropanol (3:1). 2-MTHF is significantly more polar than hexanes, but less polar than
isopropyl alcohol according to the solvent polarity scale.132,133 Thus, it should perform similarly
or slightly better than traditional HIPA solvents in extraction of active organic components.
Additionally, 2-MTHF is considered a green-solvent because of its low environmental impact, its
recovery capacity in reactions, and its renewable sourcing.132,134,135
Material and Methods
Microalgae
All species of algae were obtained from NCMA Bigelow Laboratory and UTEX as
axenic cultures. Algal cultures were maintained as axenically as possible in media and lighting
conditions described by the manufacturer to produce a 4-liter culture with a cell concentration of
6 x 106 per mL. Prior to pelleting, algal cultures were tested for the presence of bacteria using
PCR (Appendix A). Species used in this study include: Botryococcus braunii 572,
Nanochloropsus oculata 2164, Rhodomonas lens 739, Tisochrysis lutea 463 and
Chlorochromonas danica 3279. Algal growth media, enriched seawater (L1), modified Bold’s
3N medium (MB3N), Erdschreiber’s medium, tris-acetate-phosphate (TAP), and Ochromonas
media, were prepared in lab using recipes obtained from the National Center of Marine Algae
(NCMA) Bigelow Laboratory or the University of Texas Culture Collection (UTEX) and
sterilized.
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Table 2. Algae Species and Extracts
Algae Species (UTEX/NCMA ID)

Extraction Solvent

Label

Tisochrysis lutea (463)

HIPA

T. lutea [H]

Tisochrysis lutea (463)

2-MTHF

T. lutea [M]

Rhodomonas lens (739)

HIPA

R. lens [H]

Rhodomonas lens (739)

2-MTHF

R. lens [M]

Botryococcus braunii (572)

HIPA

B. braunii [H]

Botryococcus braunii (572)

2-MTHF

B. braunii [M]

Chlorochromonas danica (3279)

HIPA

C. danica [H]

Chlorochromonas danica (3279)

2-MTHF

C. danica [M]

Nanochloropsus oculata (2164)

HIPA

N. oculata [H]

Nanochloropsus oculata (2164)

2-MTHF

N. oculata [M]

Bacterial Cultures
Bacterial cultures were grown and stored at 30o C in nutrient broth (NB).
Stenotrophomonas maltophilia 13637 was obtained from ATCC and grown in nutrient broth
overnight to a McFarland standard of 0.5.
Fungal Cultures
Cultures of Candida albicans wild-type SC5314 were generously donated by Dr.
Cristopher Pierce at the University of the Incarnate Word, Biology Department. Yeast cultures
were grown at 30o in YPD.
Chemicals
All chemicals used were reagent grade, including 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT), 2,2’-azinobis-(3ethylbenzothiazolin-6-sulfonic acid)
diammonium salt (ABTS), Folin-Ciocalteu’s reagent, 6-hydroxy-2,5,7,8-tetramethylchromane-2carboxylic acid (Trolox), potassium persulfate, gallic acid, 2-(3,4-dihydroxyphenyl)-3,5,7trihydroxy-4H-chromen-4-one (quercetin), crystal violet (CV), 2-methyltetrahydrofuran (2-
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MTHF), and aluminum chloride (AlCl3). All buffers, media, antibiotics, and solvents were
obtained from Sigma Aldrich or Cayman Chemicals.
Pelleting and Extraction
Extraction was completed as described in Pane with slight modification.67 Briefly, upon
reaching a threshold of 6 x 106 cell per mL in a 4-liter volume, algal cultures were centrifuged
for 20 min at 3500 rpm and -4o C. The resulting cell pellets were stored at -80oC for no longer
than 4 weeks. Each pellet was evenly divided for extraction with either 3:1 hexanes/isopropanol
(HIPA) or 2-methyltetrahydrofuran (2-MTHF). Extraction with either solvent was initiated with
a volume of solvent equal to the volume of the pellet to be extracted. Each pellet was then
sonicated for 5 minutes on ice, and centrifuged at 5000 rpm for 10 min at -4o C. The process was
repeated with additional equivalents of solvent until the pellet showed significant color loss. The
resulting organic layer was stored in a clean glass vial and its solvent was evaporated under
stream of air. The final crude extraction residue was reconstituted in 2mL of acetonitrile and
stored at -60o C.
Determining Crude Extraction Component Concentration
The mass of the extracted residue from each algal culture was determined by transferring
500µL of its reconstituted extract to a pre-weighed glass vial and evaporating the solvent to yield
a portion of the original extracted residue. This residue was weighed to obtain a crude extracted
mass, then reconstituted in 500µL of acetonitrile.
Antioxidant Capacity Assay. The total antioxidant capacity (TAC) of extracts was
evaluated using an ABTS●+ method specialized for evaluating highly pigmented algal
extracts.136,137 A standard curve was generated using a water-soluble vitamin E derivative, Trolox
(4µM-0.05µM; R2 = 0.9581). Absorbance was measured at 734nm, for 6 minutes. The TAC
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reported for each extract was obtained by determining the difference in the absorbances at 6 min
for the extract and the corresponding absorbance for the ethanol control (negative quench
control) Difference in absorbances was then used in reference to Trolox standards, and the
results expressed as micromolar Trolox equivalents per gram of crude extracted residue (mcM
TE/g).
Estimation of Phenolic Content in Crude Algal Extracts. Total phenol concentration
was determined using Folin-Ciocalteu method.136 A 1:10 dilution of Folin-Ciocalteau reagent (FC) was made with water. Briefly, 100µL of F-C was added to either 10µL of extract and 10µL of
ethanol or 20µL of ethanol (negative phenolic control) in triplicate wells of a 96-well
polystyrene plate and incubated at room temperature for 4 minutes. Then, 80µL of saturated
sodium carbonate was added to all wells, and the plate incubated at room temperature for an
additional 2 hours. Absorbance was measured at 765 nm. A standard curve was generated using
a gallic acid (0.40-0.025 mg/mL) with an R2=0.9452. Measurements were then expressed as
milligram equivalents of gallic acid per gram crude extracted residue (mg GAE/g).
Determination of Flavonoid Content. The flavonoid content was estimated according to
the method of Ordonez et al.138 A stock solution of quercetin was created in ethanol
(0.25g/500mL), and a 2% w/v solution of AlCl3. Briefly, 10 µL of extract or 10 µL of ethanol
(as negative control) were added to 40µL of ethanol and 50 µL of AlCl3 solution (2% w/v) a 96well polystyrene plate and incubated for 1 hr at room temperature. A standard curve was
prepared using dilutions of quercetin (0.025mg/mL-0.001mg/mL; R2=0.9175). Flavonoid content
is expressed as milligram equivalents of quercetin per gram crude extracted residue (mg QE/g).
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Biofilm Formation Assay
Biofilm formation assays using crystal violet staining were carried out in 96-well
polystyrene plates as previously described by O’Toole.30 Control samples contain 10µL of
acetonitrile instead of 10µL of extract. Absorbance measurements were made in stained wells at
570nm. Each extract and control were carried out in triplicate for two separate trials.
Established Biofilm Assay. S. maltophilia biofilms were prepared in 96-well polystyrene
plates according to O’Toole and verified by absorbance of rinsed wells at 600nm to verify value
greater than 0.5. Dilutions of antibiotics were prepared in NB to make the following media
concentrations: 128µg/mL Aztreonam, 64µg/mL Ceftriaxone, and 32µg/mL of Gentamycin.
Each antibiotic media (100µL) was added to filmed wells with either 10µL of extract or 10µL of
ethanol (negative control). Additional control groups were maintained with 10µL of pure
solvent, acetonitrile. Plates were incubated for 24 hours, washed with PBS three times, and
stained for 15 minutes with crystal violet. Stained wells were rinsed three times with water and
the remaining stain solubilized in 30% acetic acid. Absorbance measurements were performed at
570 nm. Results are the average of triplicates from two trials.
The established biofilm assay procedure was followed for C. albicans, with the following
minor modifications: a cell count of 6 x 108 cells/mL was established for the overnight C.
albicans stock culture grown in yeast extract peptone dextrose (YPD); and YPD medium was
replaced with RPMI for biofilm assays and overnight incubation at 37o C.
Cell Viability Assay. Cell viability was measured in biofilm formation assays and in
established biofilm assays by treatment of live cultures with 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) according to the manufacturer’s protocol. The procedures
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for both assays were as described above but with MTT treatment and incubation in place of CV
staining. Absorbance measurements were performed at 570 nm.
Planktonic Growth Assay. Overnight cultures of S. maltophilia were grown in NB at
30oC, diluted (1:100) in NB, and added (100 µL) to each well of a 96-well polystyrene plate. To
the diluted culture was added either 10µL of extract, 10µL of extract dilution (1:1, 1:10, 1:100),
10 µL of acetonitrile (negative control) or 10 µL of an antibiotic dilution (256µg/mL, 128µg/mL,
64µg/mL, and 32µg/mL). Plates were incubated for 16 hours at 30oC. Absorbance
measurements were made at 570nm to determine planktonic growth. Planktonic growth assay
data is given in Appendix B.
Statistics. Spectroscopy measurements were made using Tecan Infinite 200 Pro plate
reader. Results are displayed as means with error bars representing standard deviation. All
experiments were carried out twice, independently. Biofilm assays were completed in triplicates,
while planktonic growth rate was completed in duplicates. All data was compiled and analyzed
using IBM SPSS 25. Analysis was conducted using one-way analysis of variance (ANOVA)
with post-hoc Dunnets and Tukey’s test, Kruskal-Wallis, and Mann-Whitney U tests. All
statistical significance was determined at p < 0.05. Statistical analyses are presented in Appendix
C.
RESULTS
Comparison of Solvents
The mass of extracted residue from each algal culture pellet and each of the extraction
solvents, 3:1 (v/v) hexanes/isopropanol (HIPA) or 2-methyltetrahydrofuran (MTHF) was
determined as described in the Materials and Methods section (Table 3). The amount of crude
material extracted from the selected species may reflect the differential solubility of molecular
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components expected from the selected algal species in these two solvent systems. Both B.
braunii and C. danica gave significantly less crude extract with HIPA as extraction solvent than
with MTHF. Extraction masses were similar between the two solvents for the other species
tested.
Table 3. Crude Extracted Mass
Algal Extract

Extracted Mass
(mg)

T. lutea [H]

21.2

T. lutea [M]

25.2

R. lens [H]

7.6

R. lens [M]

9.2

B. braunii [H]

14.8

B. braunii [M]

23.6

C. danica [H]

12.0

C. danica [M]

29.2

N. oculata [H]

10.4

N. oculata [M]

10.8

As described in Table 4, the MTHF extracts had significantly higher polyphenol concentrations
relative to the corresponding HIPA extracts for all species tested. ANOVA indicates that solvents
had a statistical significance when comparing total phenolic concentration (p = 0.008). The
extraction solvent did not demonstrate significant impacts on behavior in antimicrobial assays.
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Table 4. Evaluation of Antioxidant Capacity and Phenolic Contents of Extracts.

Algal Extract

Total Antioxidant
Capacitya
mcMol TE/g

Total Phenolic
Concentrationb
mg GAE/g

Total Flavonoid
Concentrationc
mg QE/g

T. lutea [H]

330.3 ± 1.7

39.3 ± 3.8

10.3 ± 5.7

T. lutea [M]

324.7 ± 3.1

56.7 ± 6.0

6.2 ± 2.8

R. lens [H]

102.4 ± 1.8

26.4 ± 0.6

9.7 ± 2.3

R. lens [M]

187.9 ± 3.4

111.7 ± 3.3

7.4 ± 2.0

B. braunii [H]

289.7 ± 1.6

58.6 ± 0.7

4.7 ± 0.6

B. braunii [M]

303.9 ± 2.7

116.7 ± 3.1

2.2 ± 6.6

C. danica [H]

111.0 ± 0.3

34.1 ± 0.4

3.8 ± 0.6

C. danica [M]

229.2 ± 1.4

111.2 ± 5.6

10.4 ± 3.4

N. oculata [H]

105.9 ± 2.3

52.5 ± 2.0

4.4 ± 0.6

N. oculata [M]

126.8 ± 2.8

81.4 ± 2.3

6.5 ± 0.4

a

Standardized to Trolox regression and presented as µM Trolox equivalents (TE) per g.
Standardized to gallic acid regression and presented as mg gallic acid equivalents (GAE) per g.
c
Standardized to quercetin regression and presented as mg quercetin equivalents (QE) per gram.
± indicates standard deviation.
b

Impact on Planktonic Growth
Planktonic cultures of S. maltophilia were treated with crude algal extracts according to
the method described by the Clinical and Laboratory Standards Institute as a means of assessing
the sensitivity of free-living cells to growth inhibition or bactericidal activity in the extracts. The
undiluted extract along with three dilutions (1:1, 1:10, and 1:100) in acetonitrile were examined.
For verification, the same method was used to determine a minimum inhibitory concentration
(MIC) for gentamicin, aztreonam, and ceftriaxone. None of the algal extracts tested showed
significant planktonic growth inhibition, and the sensitivity of planktonic S. maltophilia to the
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antibiotics tested was as expected, with aztreonam demonstrating the least effective growth
inhibition of S. maltophilia (Appendix B).
Impact on Biofilm Formation in S. maltophilia
Because biofilm formation in S. maltophilia has been demonstrated to involve signal
mediation through the diffusible signal factor (DSF) system, the disruption of the filming process
by a crude algal extract may indicate interference with the DSF machinery by components within
the extract.139 Therefore, the formation of biofilm by S. maltophilia was evaluated with and
without the presence of crude algal extracts, examining both the relative mass of formed biofilm
and the cell viability within the formed film.
As indicated in Table 5, there was not a significant reduction in the formation of the
biofilms created by S. maltophilia. The addition of extract before the formation of a biofilm had
little effect on the organism’s ability to generate a biofilm.
Table 5. Impact of Extracts on Biofilm Formation by S. maltophilia.

a

Extract

Normalized Film Biomassab

T. lutea [H]

83.8% ± 6.6

T. lutea [M]

83.5% ± 3.4

R. lens [H]

89.4% ± 4.8

R. lens [M]

92.5% ± 11.9

C. danica [H]

73.3% ± 6.8

C. danica [M]

80.3% ± 11.2

N. oculata [H]

85.5% ± 12.0

N. oculata [M]

84.6% ± 17.5

B. braunii [H]

82.0% ± 10.7

B. braunii [M]

81.2% ± 8.6

All percentages are normalized to untreated S. maltophilia and ± represents standard deviation.
Biomass is estimated from CV absorbance and indicates the formation of a biofilm.

b
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Impact on Established Biofilms
Overnight biofilms were generated and incubated with 10µL of algal extract. Two
measurements were taken to compare the overall biomass using CV stain with viable cells using
MTT. Using a Dunnett test, each sample’s measurements were then compared to the control
group to determine statistical significance at p < 0.05. With extract only treatments, there were
no significant reductions in biomass, as evidenced by the CV percentages. B. braunii [H] (p <
0.001), B. braunii [M] (p < 0.001), C. danica [H] (p < 0.001), C. danica [M] (p = 0.001), N.
oculata [H] (p < 0.001), and N. oculata [M] (p = 0.001) all showed statistically significant
effects against viable cells as measured by their respective MTT percentages.
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Figure 19. Overnight treatment with algal extracts on established biofilms. Resulting static
biofilm formation of S. maltophilia and cellular metabolism after treatment with algal extracts
overnight. Ratios are generated to indicate general effectiveness of treatment against cells within
the biofilm. * indicates statistically significant values at p <0 .05.
Second, the algal extracts were applied in combination with the monobactam antibiotic,
Aztreonam at 128µg/mL. Control groups were treated with only 128µg/mL of Aztreonam and
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acetonitrile (ACN), the algal extract medium. As in the previous data, the respective CV and
MTT measurements were compared to their control groups to produce a percentage. The
antibiotic control groups showed almost no change compared to the non-antibiotic control in the
previous experiment, which was expected. Again, B. braunii [H] (p < 0.001), B. braunii [M] (p <
0.001), C. danica [H] (p < 0.001), C. danica [M] (p = 0.003), N. oculata [H] (p < 0.001), and N.
oculata [M] (p = 0.001) all showed statistically significant effects on cell viability. Interestingly,
C. danica [H] (p = 0.04) showed statistically significant reductions in measurable biomass also
with the addition of Aztreonam at the significance level of (p < 0.05) in the Dunnett’s analysis.
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Figure 20. Overnight treatment with algal extracts and aztreonam on established biofilms.
Resulting static biofilm formation of S. maltophilia and cellular metabolism after treatment with
algal extracts and aztreonam overnight. Ratios are generated to indicate general effectiveness of
treatment against cells within the biofilm. * indicates statistically significant values at p < 0.05
compared to control group of 128ug/mL of aztreonam only.
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Lastly, the cephalosporin, ceftriaxone at 64µg/mL, was used in combination with algal
extracts. Again, the control group was treated with 64µg/mL of ceftriaxone only with
acetonitrile. As in previous results, the CV and MTT measurements were compared to the
control group to produce a percentage. Again, B. braunii [H] (p = 0.003), B. braunii [M] (p <
0.001), C. danica [H] (p = 0.001), C. danica [M] (p = 0.005), N. oculata [H] (p < 0.001), and N.
oculata [M] (p = 0.001) all showed statistically significant results against cell viability with
reduced MTT percentages.
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Figure 21. Overnight treatment with algal extract and ceftriaxone on established biofilm.
Resulting static biofilm formation of S. maltophilia and cellular metabolism after treatment with
algal extracts and ceftriaxone overnight. Ratios are generated to indicate general effectiveness of
treatment against cells within the biofilm. *indicates statistically significant values at p < 0 .05
compared to control group of 64ug/mL of ceftriaxone only.
Gentamycin was also tested. However, the sensitivity to gentamycin made it difficult to
effectively evaluate statistically significant impacts. To test significant interactions between algal
extracts and the addition of antibiotics against cell viability an ANOVA with a multiple
comparison Tukey test was performed. Resulting analysis showed that there was no statistical
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difference in cell viability across control groups—meaning antibiotics alone were not able to
significantly reduce cell viability in established biofilms. N. oculata [M] showed statistically
significant increase in reduction with the addition of ceftriaxone versus extract only reduction (p
= 0.011); indicating an enhancement of ceftriaxone activity. No other statistical significance was
found in determining enhancement activity of algal extracts with antibiotics.
To understand if the observed effects in S. maltophilia biofilms could be applied to other
film-forming organisms, C. albicans was tested in the same manner described for S. maltophilia.
The extracts tested did not significantly impact the relative film mass accumulation by C.
albicans either alone or in combination with fluconazole (see Appendix B). However, extracts
from B. braunii, N. oculata, and C. danica improved sensitivity of established C. albicans
biofilms to fluconazole. As shown in Figure 16, cell viability was significantly reduced relative
to the fluconazole only control in the presence of extracts from these three algae. Treatment
combinations with negative impacts on biofilm cell viability in C. albicans include combinations
of 128µg/mL of fluconazole with extracts from C. danica [H] (p = 0.003) and N. oculata [H] (p
= 0.006), [M] (p = 0.009); and combinations of 256µg/mL of fluconazole with extracts from B.
braunii [M] (p = 0.004), C. danica [H] (p = 0.002), C. danica [M] (p = 0.021), and N. oculata
[M] (p = 0.042).
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MTT Absorbance of Treated C. albicans Biofilms
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Figure 22. Cell viability of C. albicans in established biofilms treated with algal extract and
fluconazole. Measurements are based on MTT absorbances and are normalized to their
respective control groups. For combined treatments, control groups were treated with acetonitrile
or fluconazole only.
The majority of treatments had little effect on cell viability, with many extracts only
treatments increasing cell viability. However, there were a few extracts that showed a
statistically significant reduction with higher concentrations of fluconazole. For treatments with
extract and 128µg/mL of fluconazole, C. danica [H] (p = 0.003), N. oculata [H] (p = 0.006), N.
oculata [M] (p = 0.009). For treatments with extract and 256µg/mL of fluconazole, B. braunii
[M] (p = 0.004), C. danica [H] (p = 0.002), C. danica [M] (p = 0.021), N. oculata [M] (p =
0.042).
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Summary of Antimicrobial Effects
A summary of the antimicrobial effects by algal extracts observed in this study is
presented in Table 6. While the extracts did not exhibit strong growth inhibitory or bactericidal
activity as single agents, the extracts in both solvent systems from B. braunii, C. Danica, and N.
oculata caused significant decreases in S. maltophilia cell viability in biofilms when combined
with either ceftriaxone or aztreonam. Extracts from these species also decreased cell viability in
Candida biofilms when combined with fluconazole. Extracts from T. lutea and R. lens
demonstrated limited impacts on either biofilm formation or antibiotic sensitivity of established
biofilms in S. maltophilia or C. albicans.
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Table 6. Summarization of Antimicrobial Effects

N. oculata [M]

N. oculata [H]

C. danica [M]

C. danica [H]

Biofilm Formation

B. braunii [M]

B. braunii [H]

S. maltophilia

Planktonic Growth

+

+

-

+

+

CV

-

-

-

-

-

-

CV

-

++

+

+

-

-

MTT

+++

+++

++

++

+++

++

CV

-

+

+

+

-

-

MTT

+++

+++

++

++

+++

+++

CV

+

+

+

-

-

-

MTT

+

+++

++

++

+++

+++

CV
MTT
CV

-

-

-

-

-

-

MTT

-

-

+

-

+

-

Extract Only

Extract +
Aztreonam

Extract +
Ceftriaxone

C. albicans

-

Extract Only
Extract + 64µg/mL
fluconazole

Extract +
CV
128µg/mL
MTT
+
+
+
+
+
fluconazole
Extract +
CV
256µg/mL
MTT
+
+
+
+
+
fluconazole
Summarization of data for raw algal extracts. Only extracts with previous statistical significance
are shown. A scale was used to present a visualization of performance across each test: ‘+’ =
reduction of 25%, ‘++’ = reduction of 50%, and ‘+++’ = reduction of 75% or more. For
planktonic growth, the greatest reduction percentage was used.
The grouped scatter plot in Figure 17 shows a pairwise ratio of CV and MTT per extract based
on extraction solvent and antibiotic combination for treatment. The overall distribution for the
extraction solvent per treatment is similar, with the most noticeable difference of no antibiotic
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(extract only). A statistical comparison of algal extracts based on extraction solvent using a
Mann-Whitney U test was performed for each treatment condition in respect to CV and MTT
percentages. Two scenarios were found to have been statistically different based on solvent: B.
braunii CV for extract only treatment (p = 0.045) and C. danica CV for “extract + Aztreonam”
(p = 0.030). All other instances showed no statistical significance between solvents per algae

CV % of control

CV % of control

CV % of control

species and antibiotic.

MTT % of control

MTT % of control

Figure 23. Solvent scatter plot of extract CV and MTT pairwise mean percentages grouped by
antibiotic. Dotted red lines indicate control group to which each series is normalized.
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Discussion and Conclusion
Extraction Solvents
Commercialized chemical processes require large amounts of solvents. With modern
safety regulations, many processes are being re-evaluated with a focus on reducing
environmental impact and increasing efficiency. Dichloromethane, diethyl ether, 1-ethyl-3methylimidazolium methyl sulfate, benzene, petroleum ether, acetone, and chloroform have all
been used as solvents and cosolvents to extract natural components, but most of these solvents
are highly toxic to wildlife and pose serious health risks to humans.140–144 Alternative solvents
that are safer and more renewably sourced such as 2-MTHF provide and attractive alternative to
traditional extraction solvents.
In the current study, two solvents were used in extraction of algal components, HIPA
(3:1) and 2-MTHF. Extracted residue masses varied by species and solvent with the largest
extracted masses seen with 2-MTHF from C. danica (14.6ug/mL), and the smallest extracted
mass with HIPA from R. lens (3.6ug/mL). Based on mass, 2-MTHF produced generally higher
yields than the HIPA except in the case of N. oculata (5.4ug/mL [M] and 5.6ug/mL [H]). As
predicted, the higher yields of 2-MTHF was also associated with greater polyphenol
concentration (p = 0.008). Improving polyphenol yield is important factor in future natural
products research because their antimicrobial potential. These experiments demonstrate that the
performance of 2-MTHF extracts in the antimicrobial assays described is comparable to the
performance of the more traditional HIPA extracts.
Impacts on S. maltophilia Biofilm Formation and Cell Viability in Established Biofilms
Biofilm protection of nosocomial pathogens is responsible for many resistant hospital
infections originating from implanted medical devices. Currently, the only way to treat such
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infections is to remove the affected device because the film cannot be disrupted or penetrated
with chemotherapy. For this reason, agents that can inhibit biofilm formation, alter biofilm
metabolism, or increase sensitivity of biofilms to existing antimicrobial agents will constitute an
important step in effectively treating biofilm-related infections. Reports describing anti-biofilm
strategies have increased in frequency, indicating that this type of intervention will continue to
be of interest amid escalations in resistant microbial infections.145,146
Biofilm formation by S. maltophilia was not significantly impacted by the crude algal
extracts tested (Table 5). However, biofilms treated with extracts from the oleaginous algae, B.
braunii and N. oculata, and the heterotrophic algae, C. danica, showed significant decreases in
cell viability relative to the untreated control (acetonitrile only). This effect was observed with
extracts from both solvent systems and was essentially the same whether the extracts were used
as single agents or in combination with aztreonam and ceftriaxone. Taken together, these results
suggest that (i) the algal extracts did not significantly impact the access or interactions of the
selected antibiotics with biofilm cells; and (ii) likely components of the extracts such as
polyphenols, quorum signaling molecules, neutral lipids, and some classes of fatty acids, have
bactericidal or bacteriostatic effects.23,68,70,118
These data may also point to the involvement of S. maltophilia biofilm hydrophobicity in
the observed effects of crude algal extracts on cell viability. Localized hydrophobic and
hydrophilic regions are found in established bacterial biofilms.101 The hydrophobicity may be
linked to discrete purposes such as water storage. Hydrophobic regions are more likely to
interact with many of the organic components of the algal extracts such as fatty acids and less
polar polyphenols. On the other hand, the antibiotics, aztreonam and ceftriaxone, while
amphipathic overall, have high polar surface area (PSA) meaning they are more likely to interact
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with hydrophilic regions. It’s possible that S. maltophilia produces largely hydrophobic ECM,
allowing penetrance of the organic components but not the antibiotics.
Impacts on C. albicans Cell Viability in Established Biofilms.
C. albicans forms robust films that are difficult to remove or degrade. These yeast films
have been shown to be highly hydrophobic due to the production, secretion, and branching of β1,3 glucan throughout the ECM.106 The branched polymers increase hydrophobicity which limits
antifungal drug penetrance. Fluconazole it often used as a first line treatment for fungal
infections, but biofilm associated C. albicans becomes exceedingly resistant. As reviewed by
Desai et al., the biofilm is the single largest factor in resistance seen in C. albicans.28
Algal extracts showed in this study demonstrated almost no effect on biofilm mass as
measured by CV staining, on their own or combined with fluconazole. However, some of the
extracts were effective in reducing cell viability in C. albicans biofilms. Interestingly, the
extracts that reduced cell viability in S. maltophilia biofilms, namely those from B. braunii, N.
oculata, and C. danica, were also effective in decreasing the cell viability of fluconazole-treated
C. albicans biofilms. Extracts did not significantly impact cell viability of C. albicans when used
as single agents but did increase sensitivity to fluconazole at higher concentrations (128 µg/mL
and 256 µg/mL). These findings may strengthen the argument for hydrophobic interactions of
extract components driving changes at the film surface, since the less polar structure of
fluconazole (relative to ceftriaxone and aztreonam) could render it more interactive with
nonpolar and amphipathic components of the extracts and thereby provide improved access for
fluconazole to filmed cells in the hydrophobic ECM of a C. albicans biofilm.
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APPENDIX A. DNA Isolation and 16S rRNA Profiling of Algal Cultures
Algal cultures were evaluated for bacterial constituency at harvest by pelleting a 2 mL volume of
culture and storing the pellet at -20°C for DNA isolation and PCR using amplification of 16S
rRNA according to the method of Krohn-Molt.147 The results of this analysis for cultures
extracted as described in these studies are given in Table AA1.
Table A1. Bacterial Constituency in Algal Cultures for Extraction.

Algal Culture

Amplification of 16S rRNA Indicating the
Presence of Bacteria

T. lutea

positive

R. lens

positive

B. braunii

positive

C. danica

positive

N. oculata

positive
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APPENDIX B. Supplementary Data

Planktonic Growth of S. maltophilia Treated with Crude Extracts
Percent Normalized to Control
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Figure B1. Impact of crude extracts on planktonic growth of S. maltophilia. All growth
percentages are normalized to untreated control group. Error bars represent standard deviation.
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Comparison of Cell Viability after Treament Planktonically or in
Established Biofilm for S. maltophilia
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Figure B2. Comparison of sensitivity to antibiotic treatment planktonically vs. in an established
biofilm. Error bars represent standard deviation.
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Planktonic Growth of S. maltophilia Treated with Antibotics

Percent Normalized to Control
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Figure B3. Impact of antibiotics on planktonic growth of S. maltophilia. All growth percentages
are normalized to an untreated control group. Error bars represent standard deviation.
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CV Absorbance of Treated C. albicans Biofilms

Percent Normalized to Control
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Figure B4. Measured biomass of established C. albicans films treated with algal extracts and
combined treatment with fluconazole. Measurements are based on CV absorbance and are
normalized to their respective control groups. For combined treatments, control groups were
treated with acetonitrile or fluconazole only.
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APPENDIX C. Statistical Analyses
Table C1. Kruskal-Wallis analysis of solvent by treatment, extract only versus extracts +
128ug/mL of aztreonam.
Test Statisticsa,b
Algae

Solvent

B. braunii

HIPA

2-MTHF

C. danica

HIPA

2-MTHF

N. oculata

HIPA

2-MTHF

a. Kruskal Wallis Test
b. Grouping Variable: Antibiotic

CV

MTT

Kruskal-Wallis H

.006

.058

df

1

1

Asymp. Sig.

.936

.810

Kruskal-Wallis H

1.452

.161

df

1

1

Asymp. Sig.

.228

.688

Kruskal-Wallis H

5.026

.026

df

1

1

Asymp. Sig.

.025

.873

Kruskal-Wallis H

.643

.103

df

1

1

Asymp. Sig.

.423

.748

Kruskal-Wallis H

.521

.162

df

1

1

Asymp. Sig.

.470

.687

Kruskal-Wallis H

2.084

.026

df

1

1

Asymp. Sig.

.149

.872
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Table C2. Kruskal-Wallis analysis of solvent by treatment, extract +128ug/mL versus
extract + 64ug/mL of ceftriaxone.
Test Statisticsa,b
Algae
Solvent
B. braunii

HIPA

2-MTHF

C. danica

HIPA

2-MTHF

N. oculata

HIPA

2-MTHF

a. Kruskal Wallis Test
b. Grouping Variable: Antibiotic

CV

MTT

Kruskal-Wallis H

.006

.161

df

1

1

Asymp. Sig.

.936

.688

Kruskal-Wallis H

1.641

.940

df

1

1

Asymp. Sig.

.200

.332

Kruskal-Wallis H

6.564

.231

df

1

1

Asymp. Sig.

.010

.631

Kruskal-Wallis H

8.337

.234

df

1

1

Asymp. Sig.

.004

.629

Kruskal-Wallis H

2.564

.058

df

1

1

Asymp. Sig.

.109

.810

Kruskal-Wallis H

2.084

.412

df

1

1

Asymp. Sig.

.149

.521
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Table C3. Kruskal-Wallis analysis of solvent by treatment, extract only versus extract +
64ug/mL of ceftriaxone.
Test Statisticsa,b
Algae

Solvent

B. braunii

HIPA

2-MTHF

C. danica

HIPA

2-MTHF

N. oculata

HIPA

2-MTHF

a. Kruskal Wallis Test
b. Grouping Variable: Antibiotic

CV

MTT

Kruskal-Wallis H

.006

.006

df

1

1

Asymp. Sig.

.936

.936

Kruskal-Wallis H

.232

.104

df

1

1

Asymp. Sig.

.630

.747

Kruskal-Wallis H

.103

.316

df

1

1

Asymp. Sig.

.749

.574

Kruskal-Wallis H

2.837

.231

df

1

1

Asymp. Sig.

.092

.631

Kruskal-Wallis H

1.859

.412

df

1

1

Asymp. Sig.

.173

.521

Kruskal-Wallis H

.641

.234

df

1

1

Asymp. Sig.

.423

.629
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Table C4. ANOVA post-hoc Dunnett test comparing corresponding control groups to
extracts and extracts with treatment against S. maltophilia.
Multiple Comparisons
Dunnett t (<control)a
Dependen

Compariso
n

Mean
Differenc

95% (CI)
Upper

Solvent

Treatment

t Variable Algae

Control

e

Sig.

Bound

HIPA

Extract Only

CV

T. lutea

Control

21.16667

.983

71.3824

R. lens

Control

36.50000

.998

86.7157

B. braunii Control

-40.00000

.124

10.2157

C. danica

Control

-45.83333

.075

4.3824

N. oculata Control

-36.16667

.167

14.0491

T. lutea

Control

-31.66667

.109

6.5945

R. lens

Control

-12.83333

MTT

B. braunii Control
C. danica

Control

.518

25.4278

*

.000

-43.9055

*

.000

-31.0722

*

-82.16667
-69.33333

N. oculata Control

-83.83333

.000

-45.5722

T. lutea

Control

5.83333

.906

52.3670

Aztreonam

R. lens

Control

-16.66667

.493

29.8670

(128ug/mL)

B. braunii Control

-33.50000

.167

13.0337

.004

-20.9663

with

CV

C. danica
MTT

Control

*

-67.50000

N. oculata Control

-48.66667* .040

-2.1330

T. lutea

-32.33333

R. lens

Control
Control

.056

.8336

*

.030

-3.3331

*

-36.50000

B. braunii Control

-77.50000

.000

-44.3331

C. danica

-69.00000* .000

-35.8331

Control

*

N. oculata Control

-82.33333

.000

-49.1664

T. lutea

Control

16.83333

.953

82.3827

Ceftriaxone

R. lens

Control

-31.33333

.368

34.2161

(64ug/mL)

B. braunii Control

-9.33333

.717

56.2161

C. danica

-41.83333

.225

23.7161

-9.16667

.719

56.3827

.029

-4.3707

with

CV

Control

N. oculata Control
MTT

*

T. lutea

Control

-44.50000

R. lens

Control

-51.00000* .012

B. braunii Control
C. danica

Control

N. oculata Control

-10.8707

*

.003

-21.2040

*

.001

-28.2040

*

.000

-45.8707

-61.33333
-68.33333
-86.00000
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2-MTHF

Extract Only

CV

MTT

T. lutea

Control

41.33333

.998

100.0748

R. lens

Control

49.33333

.999

108.0748

B. braunii Control

-64.83333* .030

-6.0919

C. danica

-48.33333

.111

10.4081

N. oculata Control

.16667

.835

58.9081

T. lutea

Control

-26.83333

.174

10.9762

R. lens

Control

-24.16667

Control

.224

13.6429

*

.000

-52.0238

*

.001

-24.0238

N. oculata Control

-68.16667* .000

-30.3571

T. lutea

Control

33.83333

.999

76.9529

R. lens

Control

-9.00000

.652

34.1195

B. braunii Control
C. danica
with

CV

Aztreonam
(128ug/mL)

MTT

Control

-89.83333
-61.83333

*

B. braunii Control

-71.50000

.001

-28.3805

C. danica

-56.83333* .009

-13.7138

N. oculata Control

-30.50000

.176

12.6195

T. lutea

Control

-29.83333

.156

10.5578

R. lens

Control

-15.83333

.457

24.5578

Control

B. braunii Control

-81.83333* .000

-41.4422

C. danica

-62.16667* .003

-21.7755

Control

*

N. oculata Control

-70.16667

.001

-29.7755

T. lutea

Control

42.83333

.999

91.6920

Ceftriaxone

R. lens

Control

-28.66667

.267

20.1920

(64ug/mL)

B. braunii Control

-51.50000* .038

-2.6413

C. danica

-28.66667

.267

20.1920

N. oculata Control

19.00000

.979

67.8587

T. lutea

Control

-49.33333* .023

-6.6864

R. lens

Control

-22.16667

with

CV

MTT

Control

B. braunii Control
C. danica

Control

N. oculata Control

.327

20.4802

*

.000

-45.0198

*

.005

-17.6864

-70.16667* .001

-27.5198

-87.66667
-60.33333

*. The mean difference is significant at the 0.05 level.
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.
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Table C5. Mann-Whitney U comparison of component concentration by extraction solvent.

Test Statisticsa
Antioxidant

Polyphenols

Flavonoid

Mann-Whitney U

6.000

0.000

12.000

Wilcoxon W

21.000

15.000

27.000

Z

-1.358

-2.611

-0.104

Asymp. Sig. (2-tailed)

0.175

0.009

0.917

Exact Sig. [2*(1-tailed Sig.)]

0.222b

0.008

1.000b

a. Grouping Variable: Solvent
b. Not corrected for ties.

Table C6. ANOVA post-hoc Dunnett test comparing control group to extracts with
64ug/mL of fluconazole against C. albicans.
Mean

95% (CI) Upper

Dunnett t (<control)b

Extract

Comparison

Difference

Sig.

Bound

T. lutea [H]

Control

0.4727

1.000

0.74492

T. lutea [M]

Control

0.0775

0.986

0.34876

R. lens [H]

Control

0.3831

1.000

0.65540

R. lens [M]

Control

0.7923

0.987

0.35104

B. braunii [H]

Control

1.0309*

0.994

0.37530

B. braunii [M]

Control

-3.0607

0.024

-0.03385

C. danica [H]

Control

-0.3855*

0.003

-0.11330

C. danica [M]

Control

-0.2550

0.071

0.01716

N. oculata [H]

Control

-0.3619*

0.006

-0.08977

N. oculata [M]

Control

-0.3457*

0.009

-0.07356

*The mean difference is significant at the 0.05 level.
b. the Dunnett t-tests treat one group as a control and compare all other groups against it.
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Table C7. ANOVA post-hoc Dunnett test comparing control group to extracts with
128ug/mL of fluconazole against C. albicans.
Mean

95% (CI) Upper

Dunnett t (<control)b

Extract

Comparison

Difference

Sig.

Bound

T. lutea [H]

Control

0.3692

1.000

0.74492

T. lutea [M]

Control

0.1832

1.000

0.34876

R. lens [H]

Control

0.1620

0.999

0.65540

R. lens [M]

Control

0.0530

0.975

0.35104

B. braunii [H]

Control

0.0291

0.954

0.37530

B. braunii [M]

Control

-0.3592*

0.004

-0.03385

C. danica [H]

Control

-0.3883*

0.002

-0.11330

C. danica [M]

Control

-0.2995*

0.021

0.01716

N. oculata [H]

Control

-0.2475

0.067

-0.08977

N. oculata [M]

Control

-0.2696*

0.042

-0.07356

*The mean difference is significant at the 0.05 level.
b. the Dunnett t-tests treat one group as a control, and compare all other groups against it.
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Table C8. C. albicans MTT ANOVA test by treatment, grouped by extraction solvent.
ANOVA
Species

Solvent

Control

Control

T. lutea

HIPA

2MTHF
R. lens

HIPA

2MTHF
B. braunii HIPA

2MTHF
C. danica HIPA

2MTHF
N.
oculata

HIPA

2MTHF

Sum of Squares df

Mean
Square

F

Sig.

.113

.893

Between Groups .009

2

.004

Within Groups

.936

24

.039

Total

.945

26

Between Groups .011

2

.006

Within Groups

.007

6

.001

Total

.018

8

Between Groups .045

2

.023

Within Groups

.038

6

.006

Total

.084

8

Between Groups .005

2

.002

Within Groups

.010

6

.002

Total

.014

8

Between Groups .000

2

.000

Within Groups

.011

6

.002

Total

.011

8

Between Groups .000

2

.000

Within Groups

.000

6

.000

Total

.000

8

Between Groups .000

2

.000

Within Groups

.000

6

.000

Total

.000

8

Between Groups .001

2

.000

Within Groups

.001

6

.000

Total

.002

8

Between Groups .002

2

.001

Within Groups

.004

6

.001

Total

.006

8

Between Groups .000

2

.000

Within Groups

.000

6

.000

Total

.001

8

Between Groups .004

2

.002

Within Groups

.001

6

.000

.005

8

Total

4.630 .061

3.520 .097

1.373 .323

.034

.967

4.009 .078

2.298 .182

1.961 .221

1.767 .249

.497

.631

9.786 .013
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Table C9. Multiple Comparison analysis using Tukey HSD and Dunnett test for S.
maltophilia cell viability.
(I)

(J)

Mean

Upper

Species

Solvent

Treatment

Comparison

Difference (I-J)

Std. Error

Control

Control Tukey HSD

No

Aztreonam

.03268888

.09310048 .934

.2651875

Antibiotic

Ceftriaxone

.04223332

.09310048 .893

.2747319

Aztreonam

No Antibiotic

-.03268888

.09310048 .934

.1998097

Ceftriaxone

.00954444

.09310048 .994

.2420431

No Antibiotic

-.04223332

.09310048 .893

.1902653

Aztreonam

-.00954444

.09310048 .994

.2229542

No

Aztreonam

.03268888

.09706698 .981

.2908266

Antibiotic

Ceftriaxone

.04223332

.09562820 .959

.2969348

Aztreonam

No Antibiotic

-.03268888

.09706698 .981

.2254489

Ceftriaxone

.00954444

.08623426 .999

.2381008

No Antibiotic

-.04223332

.09562820 .959

.2124682

Aztreonam

-.00954444

.08623426 .999

.2190119

Ceftriaxone

Dunnett T3

Ceftriaxone

HIPA

Aztreonam

No Antibiotic

-.03268888

.09310048 .914

.1860421

a

Ceftriaxone

No Antibiotic

-.04223332

.09310048 .863

.1764977

No

Aztreonam

-.06550001

.02832428 .130

.0214067

Antibiotic

Ceftriaxone

-.08126667

.02832428 .064

.0056400

Aztreonam

No Antibiotic

.06550001

.02832428 .130

.1524067

Ceftriaxone

-.01576666

.02832428 .847

.0711400

No Antibiotic

.08126667

.02832428 .064

.1681733

Aztreonam

.01576666

.02832428 .847

.1026733

No

Aztreonam

-.06550001

.03319070 .305

.0785623

Antibiotic

Ceftriaxone

-.08126667

.03084062 .204

.0773878

Aztreonam

No Antibiotic

.06550001

.03319070 .305

.2095623

Ceftriaxone

-.01576666

.01881562 .792

.0613290

No Antibiotic

.08126667

.03084062 .204

.2399211

Aztreonam

.01576666

.01881562 .792

.0928623

No Antibiotic

.06550001

.02832428 .103

.1465853

Tukey HSD

Ceftriaxone

Dunnett T3

Ceftriaxone

Dunnett t (2-

2MTHF

Bound

Dunnett t (2sided)
T. lutea

Sig.

Aztreonam

sided)a

Ceftriaxone

No Antibiotic

.08126667

.02832428 .050

.1623520

Tukey HSD

No

Aztreonam

.14376667

.06540351 .150

.3444426

Antibiotic

Ceftriaxone

.15606667

.06540351 .118

.3567426

Aztreonam

No Antibiotic

-.14376667

.06540351 .150

.0569092

Ceftriaxone

.01229999

.06540351 .981

.2129759

No Antibiotic

-.15606667

.06540351 .118

.0446092

Ceftriaxone

*
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Dunnett T3

Aztreonam

-.01229999

.06540351 .981

.1883759

No

Aztreonam

.14376667

.07994726 .409

.6391663

Antibiotic

Ceftriaxone

.15606667

.07968616 .367

.6569375

Aztreonam

No Antibiotic

-.14376667

.07994726 .409

.3516330

Ceftriaxone

.01229999

.00956068 .559

.0520184

No Antibiotic

-.15606667

.07968616 .367

.3448041

Aztreonam

-.01229999

.00956068 .559

.0274184

Ceftriaxone

Dunnett t (2-

Aztreonam

No Antibiotic

-.14376667

.06540351 .119

.0434672

a

Ceftriaxone

No Antibiotic

-.15606667

.06540351 .093

.0311672

No

Aztreonam

.04476667

.03318984 .422

.1466022

Antibiotic

Ceftriaxone

.05006667

.03318984 .352

.1519022

Aztreonam

No Antibiotic

-.04476667

.03318984 .422

.0570689

Ceftriaxone

.00530000

.03318984 .986

.1071355

No Antibiotic

-.05006667

.03318984 .352

.0517689

Aztreonam

-.00530000

.03318984 .986

.0965355

No

Aztreonam

.04476667

.04059443 .673

.2958170

Antibiotic

Ceftriaxone

.05006667

.04041899 .613

.3047969

Aztreonam

No Antibiotic

-.04476667

.04059443 .673

.2062836

Ceftriaxone

.00530000

.00480555 .658

.0270941

No Antibiotic

-.05006667

.04041899 .613

.2046636

Aztreonam

-.00530000

.00480555 .658

.0164941

sided)
R. lens

HIPA

Tukey HSD

Ceftriaxone

Dunnett T3

Ceftriaxone

Dunnett t (2-

Aztreonam

No Antibiotic

-.04476667

.03318984 .360

.0502476

a

Ceftriaxone

No Antibiotic

-.05006667

.03318984 .295

.0449476

No

Aztreonam

.00400000

.03495912 .993

.1112642

Antibiotic

Ceftriaxone

.00906667

.03495912 .964

.1163308

Aztreonam

No Antibiotic

-.00400000

.03495912 .993

.1032642

Ceftriaxone

.00506666

.03495912 .989

.1123308

No Antibiotic

-.00906667

.03495912 .964

.0981975

Aztreonam

-.00506666

.03495912 .989

.1021975

No

Aztreonam

.00400000

.03911431 .999

.1748729

Antibiotic

Ceftriaxone

.00906667

.03862196 .992

.1818146

Aztreonam

No Antibiotic

-.00400000

.03911431 .999

.1668729

Ceftriaxone

.00506666

.02539361 .995

.1003199

No Antibiotic

-.00906667

.03862196 .992

.1636813

Aztreonam

-.00506666

.02539361 .995

.0901865

sided)
2-

Tukey HSD

MTHF

Ceftriaxone

Dunnett T3

Ceftriaxone

Dunnett t (2-

Aztreonam

No Antibiotic

-.00400000

.03495912 .990

.0960792

a

Ceftriaxone

No Antibiotic

-.00906667

.03495912 .952

.0910126

Aztreonam

.00103334

.00438558 .970

.0144895

sided)
HIPA

Tukey HSD
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B.

No

Ceftriaxone

.01123333

.00438558 .094

.0246895

braunii

Antibiotic
No Antibiotic

-.00103334

.00438558 .970

.0124228

Ceftriaxone

.01020000

.00438558 .127

.0236562

No Antibiotic

-.01123333

.00438558 .094

.0022228

Aztreonam

-.01020000

.00438558 .127

.0032562

No

Aztreonam

.00103334

.00465140 .993

.0236994

Antibiotic

Ceftriaxone

.01123333

.00507959 .236

.0321905

Aztreonam

No Antibiotic

-.00103334

.00465140 .993

.0216327

Ceftriaxone

.01020000

.00320347 .098

.0232217

No Antibiotic

-.01123333

.00507959 .236

.0097239

Aztreonam

-.01020000

.00320347 .098

.0028217

Aztreonam

Ceftriaxone

Dunnett T3

Ceftriaxone

Dunnett t (2-

Aztreonam

No Antibiotic

-.00103334

.00438558 .960

.0115215

a

Ceftriaxone

No Antibiotic

-.01123333

.00438558 .074

.0013215

No

Aztreonam

-.00080000

.00461142 .984

.0133491

Antibiotic

Ceftriaxone

.00813333

.00461142 .259

.0222824

Aztreonam

No Antibiotic

.00080000

.00461142 .984

.0149491

Ceftriaxone

.00893334

.00461142 .209

.0230824

No Antibiotic

-.00813333

.00461142 .259

.0060158

Aztreonam

-.00893334

.00461142 .209

.0052158

No

Aztreonam

-.00080000

.00528646 .998

.0322611

Antibiotic

Ceftriaxone

.00813333

.00203087 .105

.0199117

Aztreonam

No Antibiotic

.00080000

.00528646 .998

.0338611

Ceftriaxone

.00893334

.00563245 .452

.0370869

No Antibiotic

-.00813333

.00203087 .105

.0036451

Aztreonam

-.00893334

.00563245 .452

.0192202

sided)
2-

Tukey HSD

MTHF

Ceftriaxone

Dunnett T3

Ceftriaxone

Dunnett t (2-

Aztreonam

No Antibiotic

.00080000

.00461142 .978

.0140013

a

Ceftriaxone

No Antibiotic

-.00813333

.00461142 .212

.0050680

No

Aztreonam

-.00580000

.01281622 .895

.0335237

Antibiotic

Ceftriaxone

.01850000

.01281622 .379

.0578237

Aztreonam

No Antibiotic

.00580000

.01281622 .895

.0451237

Ceftriaxone

.02430000

.01281622 .220

.0636237

No Antibiotic

-.01850000

.01281622 .379

.0208237

Aztreonam

-.02430000

.01281622 .220

.0150237

No

Aztreonam

-.00580000

.01494334 .968

.0737926

Antibiotic

Ceftriaxone

.01850000

.00651869 .115

.0429993

Aztreonam

No Antibiotic

.00580000

.01494334 .968

.0853926

Ceftriaxone

.02430000

.01506553 .446

.1025038

sided)
C.

HIPA

Tukey HSD

danica

Ceftriaxone

Dunnett T3
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Ceftriaxone

-.02430000

.01506553 .446

.0539038

.00580000

.01281622 .866

.0424897

Ceftriaxone

No Antibiotic

-.01850000

.01281622 .320

.0181897

No

Aztreonam

-.01906666

.01973566 .623

.0414878

Antibiotic

Ceftriaxone

.01803334

.01973566 .652

.0785878

Aztreonam

No Antibiotic

.01906666

.01973566 .623

.0796211

Ceftriaxone

.03710000

.01973566 .224

.0976544

No Antibiotic

-.01803334

.01973566 .652

.0425211

Aztreonam

-.03710000

.01973566 .224

.0234544

No

Aztreonam

-.01906666

.02353298 .806

.0753809

Antibiotic

Ceftriaxone

.01803334

.01427974 .583

.0867445

Aztreonam

No Antibiotic

.01906666

.02353298 .806

.1135142

Ceftriaxone

.03710000

.02026763 .383

.1475928

No Antibiotic

-.01803334

.01427974 .583

.0506778

Aztreonam

-.03710000

.02026763 .383

.0733928

Tukey HSD

Ceftriaxone

Dunnett t (2-

Aztreonam

No Antibiotic

.01906666

.01973566 .558

.0755649

sided)a

Ceftriaxone

No Antibiotic

-.01803334

.01973566 .589

.0384649

Tukey HSD

No

Aztreonam

.00600000

.00725243 .701

.0282525

Antibiotic

Ceftriaxone

.00650000

.00725243 .662

.0287525

Aztreonam

No Antibiotic

-.00600000

.00725243 .701

.0162525

Ceftriaxone

.00050000

.00725243 .997

.0227525

No Antibiotic

-.00650000

.00725243 .662

.0157525

Aztreonam

-.00050000

.00725243 .997

.0217525

No

Aztreonam

.00600000

.00613732 .721

.0323935

Antibiotic

Ceftriaxone

.00650000

.00836381 .823

.0383162

Aztreonam

No Antibiotic

-.00600000

.00613732 .721

.0203935

Ceftriaxone

.00050000

.00708331 1.000 .0332197

No Antibiotic

-.00650000

.00836381 .823

Aztreonam

-.00050000

.00708331 1.000 .0322197

oculata

Ceftriaxone

Dunnett T3

Ceftriaxone

.0253162

Dunnett t (2-

Aztreonam

No Antibiotic

-.00600000

.00725243 .642

.0147619

a

Ceftriaxone

No Antibiotic

-.00650000

.00725243 .600

.0142619

No

Aztreonam

-.02160000

.01165965 .232

.0141750

sided)

MTHF

Aztreonam
No Antibiotic

Dunnett T3

2-

.0059993

Aztreonam

Ceftriaxone

HIPA

.00651869 .115

a

MTHF

N.

-.01850000

Dunnett t (2sided)
2-

No Antibiotic

Tukey HSD

Antibiotic

Ceftriaxone

-.05136667

.01165965 .011

-.0155917

Aztreonam

No Antibiotic

.02160000

.01165965 .232

.0573750

Ceftriaxone

-.02976667

.01165965 .095

.0060083

No Antibiotic

.05136667*

.01165965 .011

.0871417

Aztreonam

.02976667

.01165965 .095

.0655417

Ceftriaxone

*
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Dunnett T3

No

sided)

a

-.02160000

.01062811 .267

.0197654

Antibiotic

Ceftriaxone

-.05136667

.01147422 .036

-.0051707

Aztreonam

No Antibiotic

.02160000

.01062811 .267

.0629654

Ceftriaxone

-.02976667

.01277606 .191

.0183843

No Antibiotic

.05136667*

.01147422 .036

.0975626

Aztreonam

.02976667

.01277606 .191

.0779177

No Antibiotic

.02160000

.01165965 .189

.0549787

.01165965 .008

.0847453

Ceftriaxone

Dunnett t (2-

Aztreonam

Aztreonam
Ceftriaxone

No Antibiotic

*

*

.05136667

*. The mean difference is significant at the 0.05 level.
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.

